CLL Coverage from Every Angle

Jennifer R. Brown, MD, PhD, Clinical Strategies for Selecting Treatment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Posted: Thursday, April 1, 2021

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses the latest data on selecting treatment for patients with relapsed or refractory CLL/SLL, the factors to consider, and recommendations on following those with minimal residual disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.